Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005

Jan 15 2007

• By Mary Jo Laffler and Daniel Poppy

Related Content

MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration

May 08 2006

J&J Enters HIV Arena With Prezista; Darunavir Is Tenth Protease Inhibitor

Jul 03 2006

Tyzeka Priced Higher Than Epivir, But Lower Than Other Competitors

Nov 06 2006

Omnaris Launch Delayed While Altana Sniffs Out Marketing Partner

Oct 30 2006

Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

Jan 01 2007

2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short

Jan 15 2007

Drug Approvals Will Be Down “Significantly” In ’05, FDA’s Gottlieb Predicts

Dec 12 2005

Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18

Jan 09 2006

Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails

Dec 04 2006

Merck Re-Enters Oncology With Zolinza Approval For Rare Skin Cancer

Oct 16 2006

NMEs On The Rebound? Pace of 2006 Novel Drug Approvals Bests 2005

Sep 25 2006

Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar

Jan 30 2006

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window